Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN084, A Multi-Kinase Inhibitor to Address Tumor Resistance of Targeted Therapies
Shanghai, March 9th, 2022 - Tyligand Bioscience, a clinical-stage biotechnology company focused on developing innovative therapies against drug resistant cancers, announces that the first subject had been dosed in US in a phase 1 trial for its innovative multi-kinase inhibitor TSN084. The study includes a dose escalation and dose expansion phase to evaluate the safety, tolerability, and preliminary anti-tumor activity in subjects with advanced or metastatic malignancies, to be conducted both in US and China. The first enrollment was led by Dr. Siqing Fu, Professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented: “TSN084 is the front runner of the Tyligand pipeline of innovative molecules. It hits a unique combination of kinase targets including CDK8/19 and offers the possibility of synergistic attack against cancers at multiple fronts. We are glad that it has reached this major milestone in a journey toward becoming a drug that can help patients. We appreciate the dedication of our team members, collaborators and clinical investigators for propelling the project forward with impressive quality and speed.”
About Tyligand Bioscience (Shanghai) Limited
Tyligand Bioscience is a clinical stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors such as NSCLC and TNBC. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload discovery and development.